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MOTILITY AND VISCERAL SENSATION
Double blind, randomised, placebo controlled study of
four weeks of lansoprazole for the treatment of functional
dyspepsia in Chinese patients
W M Wong, B C Y Wong, W K Hung, Y K Yee, A W C Yip, M L Szeto, F M Y Fung,
T S M Tong, K C Lai, W H C Hu, M F Yuen, S K Lam
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Background: The use of proton pump inhibitors for the treatment of functional dyspepsia is controver-
sial and the role of Helicobacter pylori infection in functional dyspepsia is uncertain.
Aim: To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspep-
sia in Chinese patients.
Method: Patients with a clinical diagnosis of functional dyspepsia according to the Rome II criteria and
normal upper gastrointestinal endoscopy were recruited and randomised to receive: (1) lansoprazole
30 mg,(2) lansoprazole 15 mg, or (3) placebo, all given daily for four weeks. Dyspepsia symptom
scores and quality of life (SF-36 score) were evaluated before and four weeks after treatment.
Results: A total of 453 patients were randomised. There was no difference in the proportion of patients
with complete symptom relief in the lansoprazole 30 mg (23%) and lansoprazole 15 mg (23%) groups
compared with the placebo group (30%). The proportion of H pylori positive patients with a complete
response was similar with lansoprazole 30 mg (34%) and lansoprazole 15 mg (20%) versus placebo
(22%). All symptom subgroups (ulcer-like, dysmotility-like, reflux-like, and unspecified dyspepsia) had
similar proportions of patients with complete symptom relief after treatment.
Conclusion: Proton pump inhibitor treatment is not superior to placebo for the management of func-
tional dyspepsia in Chinese patients.
According to the Rome II criteria, functional dyspepsia isdefined as persistent or recurrent pain or discomfortcentred in the upper abdomen for at least 12 weeks in
the preceding 12 months.1 In the Asia Pacific region, dyspepsia
is as common as in the rest of the world, with a prevalence
varying from 10% to 20%.2–5 Functional dyspepsia or non-ulcer
dyspepsia is a common problem encountered in gastroenterol-
ogy. It is a significant cause of morbidity and time lost from
work.6 There is no definitive treatment for this condition.
However, acid suppressive therapy such as H2 antagonists or
proton pump inhibitors is commonly used for the treatment of
functional dyspepsia. There is some evidence that antisecre-
tory therapy may be effective in non-ulcer dyspepsia,
according to a meta-analysis.7 On average, H2 blockers have
been shown to produce a 20% improvement in dyspepsia
symptoms compared with placebo.8 9 Recently, two large
randomised controlled trials have been published to assess the
efficacy of proton pump inhibitors for functional
dyspepsia.10 11 The earlier trial in which patients were treated
with omeprazole 20 mg a day for four weeks showed a 10%
gain over placebo but there was no relationship with
Helicobacter pylori status.10 A higher proportion of patients with
ulcer-like and reflux-like dyspepsia had complete sympto-
matic relief with omeprazole 20 mg versus placebo but such
benefit was not observed in patients with dysmotility-like
dyspepsia. The second trial showed that a higher proportion of
H pylori positive patients went into remission using omepra-
zole 20 mg a day for two weeks compared with placebo. But no
significant benefit was observed in H pylori negative
patients.11 Another randomised controlled trial published in
abstract form compared omeprazole 20mg and placebo for the
treatment of functional dyspepsia and found a higher
complete response rate in the omeprazole group.12 There are
other trials in uninvestigated dyspepsia in the primary care
setting but they are limited by lack of blinding,13 absence of a
placebo group,14 or selection of dyspepsia subgroups.15 While
the previous randomised placebo controlled trials were done
in Western population, and with controversial results, we per-
formed a double blind placebo controlled study to assess the
efficacy of lansoprazole 30 mg and lansoprazole 15 mg versus
placebo in Chinese patients. The therapeutic benefit in H pylori
positive and H pylori negative patients was also assessed. Dys-
pepsia subgroups based on the predominant symptoms of the
patients were studied to identify potential responders to acid
suppressive therapy.
METHODS
Patient population
Consecutive patients referred to the endoscopy unit of the
Department of Medicine, Queen Mary Hospital, Department of
Medicine, Tuen Mun Hospital, and Department of Surgery,
Kwong Wah Hospital, with a clinical diagnosis of functional
dyspepsia and normal gastrointestinal endoscopywere assessed
for recruitment. Functional dyspepsia was defined as persistent
or recurrent dyspepsia (pain or discomfort centred in the upper
abdomen) with no evidence of organic disease, chronic severe
constipation, or irritable bowel syndrome to explain the symp-
toms, for at least 12 weeks, which need not be consecutive,
within the preceding 12 months, in accordance with the Rome
II criteria. Patient aged 18–80 years with symptoms of dyspep-
sia within two weeks prior to the endoscopy visit were eligible
for the study. Informed written consent was obtained from all
patients. Patients were also required to have a dyspepsia score of
greater than 16 by our validated questionnaire16 and had no
prior investigations performed for this episode of dyspepsia
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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within six months before the study. Exclusion criteria included
patients who had any erosive change in the oesophagus, stom-
ach, or duodenum, oesophageal stricture, Barrett’s oesophagus,
duodenal deformity, or gastric or duodenal ulcer; past history of
peptic ulcer disease by endoscopy or radiology; past history of
gastro-oesophageal reflux disease documented by upper endos-
copy or 24 hour oesophageal pH monitoring; severe concomi-
tant illness; pregnancy or lactation; alcohol or drug abuse; and
use of aspirin or other non-steroidal anti-inflammatory drugs,
antibiotics, H2 receptor blockers, bismuth, or proton pump
inhibitors in the preceding four weeks. Patients with classical
heartburn or acid regurgitation as their only symptom without
epigastric discomfort or pain were also excluded to avoid
recruitment of patients with undiagnosed gastro-oesophageal
reflux disease. The study was approved by the local ethics com-
mittees in the various hospitals.
Diagnosis of H pylori infection
During endoscopy, two antral biopsies and one corpus biopsy
were obtained. One antral biopsy was used for a locally
validated rapid urease test.17 The other biopsies were sent for
histological examination of H pylori status by haematoxylin-
eosin stains and Giemsa stain if necessary. Specimens were
read by experienced pathologists who were blinded to all
clinical information, including the rapid urease test results.
The definition of H pylori infection in this study required both
tests to be positive. Equivocal cases were excluded from the
study. This approach has been previously validated in our cen-
tre, with an accuracy of 100%, and less than 0.3% of cases
cannot be diagnosed by this approach.17 Both patients and the
managing physicians were blinded to H pylori status.
Treatment regimen
Patients were randomised to receive one of the following treat-
ments: (1) 30 mg of lansoprazole; (2) 15 mg of lansoprazole, or
(3) placebo, all given once daily for four weeks. Randomisation
was performed by drawing a sealed envelope that contained a
pre-assigned randomised treatment generated by computer on
entry to the study. Both the investigators and patients were
blinded to the assigned treatment throughout the study. The
lansoprazole and placebo capsules were identical in appearance.
Patients were given a diary in which they recorded side effects
and symptoms during therapy. Patients returned for follow up
four weeks later and gastroenterologists assessed their symp-
toms and quality of life. Patient compliance was checked by
counting returned studymedications. Patients were not allowed
to take antacids, H2 receptor blockers, bismuth, antibiotics, or
proton pump inhibitors during the study period.
Dyspepsia symptoms were assessed by a locally validated
dyspepsia questionnaire which consisted of 12 questions (epi-
gastric pain, upper abdominal bloating, upper abdominal dull
ache, epigastric pain before meals, epigastric pain when anx-
ious, vomiting, nausea, belching, acid regurgitation, heart-
burn, feeling of acidity in the stomach, loss of appetite) and
graded on a five point Likert scale as follows: 1 (none), no
symptoms; 2 (mild), symptoms can be easily ignored; 3 (mod-
erate), awareness of symptoms but easily tolerated; 4 (severe),
symptoms sufficient to cause interference with normal activi-
ties; 5 (incapacitating), incapacitating symptoms with an
inability to perform daily activities and/or require days off
work. Test-retest reproducibility and internal consistency were
good, with an intraclass correlation coefficient of 0.89 and
Cronbach’s alpha coefficient of 0.90. A cut off score of>16 was
discriminative between controls and dyspeptic patients, as
well as those who reported a subjective improvement in
symptoms and those who reported no change or worsening
after treatment.16 Patients were then subclassified into four
dyspepsia subgroups according to their predominant symp-
toms: (1) ulcer-like dyspepsia—predominant epigastric pain;
(2) dysmotility-like dyspepsia—predominant discomfort that
may be characterised by upper abdominal fullness, early sati-
ety, bloating, or nausea; (3) reflux-like dyspepsia—
predominant reflux symptoms (heartburn or acid regurgita-
tion); (4) unspecified—symptoms do not fulfill the criteria for
ulcer-like, dysmotility-like, or reflux-like dyspepsia. Although
reflux-like dyspepsia was discarded in the Rome II criteria, we
felt that a certain proportion of patients with functional dys-
pepsia still belong to that particular subgroup and there is
considerable overlap between functional dyspepsia and
non-erosive or negative endoscopy reflux disease.18 19 Further-
more, inclusion of reflux-like dyspepsia allows comparison
with previous randomised controlled trials.10 Quality of life
was assessed by a locally validated questionnaire (Chinese
translated form of SF-36).20 The SF-36 consisted of 11 items to
measure eight aspects of psychological general well being
(physical functioning, role physical, bodily pain, general
health, vitality, social functioning, role emotional, and mental
health).
Statistical analysis
Treatment success was defined as complete relief of epigastric
pain/discomfort (that is, no symptoms) during the last three
days of the four week treatment. The proportion of patients
with complete relief of epigastric pain/discomfort was
compared between the lansoprazole 30 mg and 15 mg groups
and the placebo group. Mean dyspepsia score and the eight
aspects of the SF-36 scores before and after treatment were
compared in the three treatment groups. The change in mean
dyspepsia score and SF-36 scores from baseline to the four
week visit were calculated and compared between the
lansoprazole 30 mg and 15 mg groups and the placebo group.
Figure 1 Flow chart of the study patients.
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Power of the study
An expected placebo complete response rate of 25% was
adopted. To detect a 20% difference in the efficacy of the two
treatment regimens versus placebo with a power of 80% and
an α error of 5%, at least 98 patients in each arm were
required. Assuming 20% of patients would dropout, at least
123 patients were required in each treatment group.
A χ2 test, Fisher’s exact test, and the Student’s t test were
used; the Mann-Whitney U (non-parametric) test was used
for data with a skewed distribution. A p value of 0.05 or less
was considered statistically significant. The intention to treat
(ITT) analysis included all patients who had taken at least one
tablet. In the per protocol (PP) analysis, patients with poor
drug compliance (<75% intake of any study drugs) and drop-
outs (due to adverse effects) were excluded. Multiple logistic
regression analysis was performed to determine the factors
(age, sex, H pylori status, smoking, alcohol intake, dyspepsia
duration, predominant symptoms, and type of treatment
given) associated with a complete response.
RESULTS
We recruited 456 eligible patients. Of these, 129 (28%) were
referred for an open access endoscopy by primary care physi-
cians and the remainder were referred by gastroenterologists.
Three had an equivocal H pylori status, leaving 453 patients for
the ITT analysis (fig 1). A total of 149 patients were
randomised to receive lansoprazole 30 mg, 152 patients were
randomised to receive lansoprazole 15 mg, and 152 patients
were randomised to receive placebo. All recruited patients
were ethnic Chinese. Baseline characteristics of the patients in
the three treatment groups are given in table 1. Compliance
was satisfactory and more than 81%, 86%, and 87% of patients
took more than 75% of the medications in the lansoprazole
30 mg, lansoprazole 15 mg, and placebo groups, respectively.
Poor compliance patients, those who refused follow up, and
those who discontinued treatment because of adverse events
were excluded from the PP analysis (n=382) (fig 1). Baseline
characteristics of the patients and their dyspepsia subtypes are
listed in table 1. Mean age of these patients was 42.4 (range
18–75) years with a median dyspepsia score of 21.0. There
were 118 males (mean age 45.3 years) and 335 females (mean
age 41.4 years). Mean age, sex distribution, smoking history,
alcohol consumption, proportion of patients with dyspepsia
for more than one year,H pylori positivity, and mean dyspepsia
score at baseline were similar between the three treatment
groups (tables 1, 3).
There was no difference in the proportions of patients with
complete symptom relief in the lansoprazole 30mg (ITT=23%,
PP=29%) and lansoprazole 15 mg (ITT=23%, PP=27%)
groups versus placebo (ITT=30%, PP=34%) (table 2). When
complete symptom relief was assessed according to symptom
subtypes, there was no difference between lansoprazole 30 mg
and lansoprazole 15 mg versus placebo for all symptom
subgroups (table 2). The presence or absence of heartburn did
not predict a complete response to lansoprazole 30 mg or lan-
soprazole 15 mg versus placebo (NS).
Helicobacter pylori (table 2)
A total of 173 patients (38%) were H pylori positive by our gold
standard. The proportion of H pylori positive patients with
complete response was similar in the lansoprazole 30 mg
(34%) and lansoprazole 15 mg (20%) groups compared with
placebo (22%) (NS). In H pylori negative patients, a complete
response rate was higher in the placebo group compared with
the lansoprazole 30 mg group (34% v 16%; p=0.01).
Table 1 Demographics of the patient population
Lansoprazole 30 mg Lansoprazole 15 mg Placebo
No of patients (intention to treat) 149 152 152
Age (y) (mean (SD)) 42.7 (12.1) 42.9 (13.5) 41.6 (13.5)
Sex (M/F) 44/105 38/114 36/116
Smokers (%) 14 11 11
Previous smoker (%) 3 3 3
Alcohol (%) 4 5 4
Duration of disease >1 y (%) 79 80 78
H pylori positive (%) 59 (40) 55 (36) 59 (39)
Predominant symptoms (%)
Ulcer-like 30 (20) 30 (20) 39 (26)
Dysmotility-like 76 (51) 87 (57) 81 (53)
Reflux-like 6 (4) 7 (5) 5 (3)
Unspecified 37 (25) 28 (18) 27 (18)
Table 2 Complete relief of dyspeptic symptoms, respective Helicobacter pylori
status, and dyspepsia subtypes of the three treatment groups
Lansoprazole 30 mg Lansoprazole 15 mg Placebo
Complete relief of symptoms
Intention to treat 23% (35/149) 23% (35/152) 30% (45/152)
(95% CI) (17–31) (17–30) (23–37)
Per protocol 29% (35/120) 27% (35/130) 34% (45/132)
(95% CI) (21–38) (20–35) (26–43)
Complete relief of symptoms
H pylori positive 34% (20/59) 20% (11/55) 22% (13/59)
H pylori negative 16% (15/90) 25% (24/97) 34% (32/93)
Complete relief of symptoms
Ulcer-like 30% (9/30) 30% (9/30) 26% (10/39)
Dysmotility-like 21% (16/76) 20% (17/87) 28% (23/81)
Reflux-like 17% (1/6) 0% (0/7) 20% (2/5)
Unspecified 24% (9/37) 32% (9/28) 37% (10/27)
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Mean dyspepsia score and quality of life assessment
(table 3)
Baseline dyspepsia scores and quality of life assessments were
similar in the three treatment groups. Mean dyspepsia score
improved in all three groups at week 4 compared with
baseline. Four parameters of quality of life assessment (role
physical, bodily pain, vitality, and role emotional) improved
significantly at week 4 compared with baseline in the
lansoprazole 30 mg group. Two parameters of quality of life
assessment (physical functioning and bodily pain) improved
significantly at week 4 compared with baseline in the
lansoprazole 15 mg group. In the placebo group, four param-
eters of quality of life assessment (role physical, bodily pain,
role emotional, and mental health) improved significantly at
week 4 compared with baseline. However, the change in mean
dyspepsia score and SF-36 score from baseline to the four
week visit were similar between lansoprazole 30 mg versus
placebo and lansoprazole 15 mg versus placebo (NS, data not
shown). Subjects were divided into those with dyspepsia
scores above and below the median score of 21.0. There were
no significant differences in complete symptom relief among
the two lansoprazole groups and the placebo group in both
subjects with moderate to severe dyspepsia (dyspepsia score
>21.0) and subjects with mild dyspepsia (dyspepsia score
<21.0)
Adverse events (fig 1)
A total of 35 patients (11 on lansoprazole 30 mg, 12 on lanso-
prazole 15mg, and 12 on placebo) discontinued treatment due
to adverse effects. In general, medications were well tolerated
in all three groups.
Factors associated with complete response
Age, sex, H pylori status, smoking, alcohol consumption, and
dyspepsia duration had no effect on the complete response rate.
Using multiple logistic regression analysis, which included the
predominant symptoms and type of treatment given in addition
to the above factors, we could not identify any particular factor
that was associated with a favourable outcome.
DISCUSSION
We have reported a double blind, randomised, placebo
controlled study of lansoprazole 30 mg and 15 mg versus pla-
cebo for the treatment of functional dyspepsia. We found that
there was no difference in the proportions of patients with
complete symptom relief between the lansoprazole 30 mg
(23%) and 15 mg (23%) groups versus the placebo group
(30%). All symptom subgroups had similar proportions of
patients with complete symptom relief after treatment. The
proportion of H pylori positive patients with a complete
response was similar in the lansoprazole 30 mg (34%) and 15
mg (20%) groups versus the placebo group (22%). However, a
higher placebo response rate was observed in the H pylori
negative group.
In contrast with the Bond and Opera studies,10 we failed to
demonstrate the beneficial effect of proton pump inhibitor
versus placebo for the treatment of functional dyspepsia. The
Bond and Opera studies reported their results in a combined
fashion, which consisted of two identically designed ran-
domised controlled trials. However, when the two trials were
analysed separately, the observed benefits were only found in
the former study. The authors attributed the observed
difference to a higher proportion of patients being recruited
Table 3 Mean dyspepsia score and SF-36 (mean (SEM)) at week 0 and week 4 in
the three treatment groups
Week 0 Week 4 p Value
Mean dyspepsia score
Lansoprazole 30 mg 21.7 (0.3) 18.6 (0.4) <0.001
Lansoprazole 15 mg 22.3 (0.4) 19.0 (0.4) <0.001
Placebo 22.1 (0.4) 18.7 (0.5) <0.001
SF36-physical functioning
Lansoprazole 30 mg 87.6 (1.1) 87.0 (1.2) NS
Lansoprazole 15 mg 88.7 (1.2) 85.6 (1.4) 0.029
Placebo 88.6 (1.1) 88.0 (1.2) NS
SF36-role physical
Lansoprazole 30 mg 58.7 (3.2) 71.8 (6.1) 0.027
Lansoprazole 15 mg 60.7 (2.9) 61.5 (3.1) NS
Placebo 66.2 (3.0) 75.3 (2.6) 0.007
SF36-bodily pain
Lansoprazole 30 mg 55.2 (1.6) 65.8 (1.6) <0.001
Lansoprazole 15 mg 56.1 (1.7) 64.4 (1.7) <0.001
Placebo 56.6 (1.6) 66.2 (1.8) <0.001
SF36-general health
Lansoprazole 30 mg 46.5 (1.4) 46.7 (1.5) NS
Lansoprazole 15 mg 45.1 (1.3) 44.6 (1.4) NS
Placebo 45.5 (1.4) 45.7 (1.6) NS
SF36-vitality
Lansoprazole 30 mg 53.0 (1.5) 57.8 (1.5) 0.004
Lansoprazole 15 mg 51.4 (1.5) 53.6 (1.7) NS
Placebo 53.7 (1.4) 54.7 (1.5) NS
SF36-social function
Lansoprazole 30 mg 55.2 (1.6) 65.8 (1.6) NS
Lansoprazole 15 mg 56.1 (1.7) 64.4 (1.7) NS
Placebo 56.6 (1.6) 66.2 (1.8) NS
SF36-role emotional
Lansoprazole 30 mg 55.7 (3.5) 62.9 (3.4) 0.039
Lansoprazole 15 mg 55.5 (3.1) 60.5 (3.3) NS
Placebo 59.6 (3.3) 71.7 (3.1) 0.001
SF36-mental health
Lansoprazole 30 mg 64.5 (1.2) 66.5 (1.2) NS
Lansoprazole 15 mg 61.8 (1.3) 63.6 (1.4) NS
Placebo 61.7 (1.4) 64.9 (1.3) 0.018
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from family practice in the Bond study compared with the
Opera study, which had a higher placebo response rate among
patients seeing a gastroenterologist. A relatively high placebo
response rate (30%) was observed in our patients who were
attended by gastroenterologists during the initial treatment
and subsequent follow up. Thus the argument proposed by
Talley et al, where patients seeing a specialist may feel more
assured after a normal upper endoscopy leading to a higher
placebo response, also applied to our patients.10
In contrast with our study, the definition of primary outcome
in the study of Blum et alwas disappearance of dyspeptic symp-
toms requiring further management after a two week course of
omeprazole 20 mg daily, omeprazole 10 mg daily, ranitidine 150
mg daily, or placebo.11 A significant therapeutic benefit was
observed only in H pylori positive patients in the omeprazole 20
mg group. However, the investigators were not blinded to the H
pylori status of the patients, which may preclude the validity of
their results. H pylori positive patients not responding to
treatment were allowed to enter into a second study to examine
the effect of H pylori eradication on functional dyspepsia. As
pointed out by McColl,21 the lower therapeutic response
observed in H pylori positive patients in all treatment groups
compared with H pylori negative patients suggested that the
investigators were much less inclined to recognise a beneficial
response inH pylori infected patients. The proportion of patients
showing a therapeutic response following omeprazole treat-
ment was greater in H pylori negative patients (71%) compared
withH pylori positive patients (59%), despite the effectiveness of
omeprazole over placebo being confined to the latter group.
Thus the much lower placebo response rate in the H pylori posi-
tive patients may have contributed to the benefit of omeprazole
versus placebo being observed only in theHpylori positive group.
Both the managing physicians and patients were blinded to the
H pylori data in our study. In contrast, we did not observe a
therapeutic benefit of lansoprazole 30mg or lansoprazole 15mg
versus placebo. The fact that a significantly higher placebo
response rate was observed inH pylori negative patients is prob-
ably a chance finding.
Classification of dyspepsia patients into symptom sub-
groups did not identify a particular subgroup that responded
better to lansoprazole treatment. It has been suggested that
atypical gastro-oesophageal reflux disease may explain the
benefit of acid suppression observed in trials of functional
dyspepsia.22–24 It should be noted that only approximately 4%
of the patients in our study reported acid reflux symptoms as
their predominant symptoms and the majority of patients had
dysmotility-like symptoms (54%) as their predominant symp-
toms. Furthermore, the presence or absence of heartburn did
not predict a complete response to lansoprazole versus
placebo. Thus the contribution of atypical gastro-oesophageal
reflux disease to a better response to lansoprazole appeared to
be small in our study.
Patients with various degree of dyspepsia were enrolled
according to the inclusion criteria, ranging from a score of 17
(mild) and above. Judging from the median dyspepsia score of
21.0, 50% of patients had a dyspepsia score of greater than
21.0, indicating that at least half had moderate to severe dys-
pepsia. Further analysis failed to show the superiority of lan-
soprazole over placebo in both the severe dyspepsia group
(those with a score >21.0) and the mild dyspepsia group
(those with a score <21.0).
In conclusion, our data suggest that a proton pump inhibi-
tor was not superior to placebo for the management of func-
tional dyspepsia in Chinese patients.
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